Incyte Corp. buy klostergang
Start price
26.06.17
/
50%
€121.30
Target price
29.10.18
€138.91
Performance (%)
-52.00%
End price
29.10.18
€58.23
Summary
This prediction ended on 29.10.18 with a price of €58.23. Massive losses of -52.00% were the result for the BUY prediction by klostergang. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Incyte Corp. | -0.661% | -0.661% | 46.852% | 20.195% |
| iShares Core DAX® | 0.985% | 8.314% | 7.032% | 49.791% |
| iShares Nasdaq 100 | 2.067% | 16.765% | 35.952% | 96.632% |
| iShares Nikkei 225® | 2.270% | 15.605% | 46.568% | 69.047% |
| iShares S&P 500 | 1.043% | 11.077% | 26.456% | 68.087% |
Comments by klostergang for this prediction
In the thread Incyte Corp. diskutieren
klostergang stimmt der Buy-Einschätzung von datca zu
klostergang stimmt am 26.06.2017 der Buy-Einschätzung von datca zu.
Überschrift: Incyte Corporation (INCY),-Kooperationen mit Novartis,Eli Lilly,Merck,MedImmune,Bristol-Myers Squibb,Genentech,Pfizer
(Laufzeit überschritten)